Diabetic Neuropathy Treatment Market to Reflect Impressive Growth Rate During 2018-2025

Market Highlights

Diabetic neuropathy is one of the most common complications of diabetes. Patients suffering from diabetic neuropathy often report burning pain in foot. The rising prevalence of diabetic neuropathy can be seen worldwide. Around 83% people in the US are suffering from diabetic neuropathy. According to Japanese study around 298 people were diagnosed with diabetic neuropathy in 2017.

The growth of the global diabetic neuropathy treatment market is driven by various factors such as an increasing global geriatric population, rising prevalence of diabetes, and poor fitness levels. However, high costs of surgery are expected to curb the growth of the global diabetic neuropathy treatment market.

According to MRFR analysis, the global diabetic neuropathy treatment market is expected to register a CAGR of 5.1% during the forecast period of 2019 to 2025 and was valued at USD 5.80 Billion by 2025.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the increasing prevalence of diabetic neuropathy and rising per capita healthcare expenditure. The diabetic neuropathy treatment market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European diabetic neuropathy treatment market has been categorized as Western Europe and Eastern Europe.

The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The diabetic neuropathy treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing patient pool of diabetic neuropathy and raising awareness about the treatment methods, the market in Asia-Pacific is expected to be the fastest-growing. The diabetic neuropathy treatment market in the Middle East & Africa has been divided into the Middle East and Africa.

Key Players

Some of the key players in the global diabetic neuropathy treatment market are Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Eli Lilly and Company (US), Johnson & Johnson (US), GlaxoSmithKline Plc (UK), Lupin Limited (India), Glenmark Pharmaceuticals Limited (India), Depomed, Inc (US), Astellas Pharma Inc (Japan), Pfizer Inc (US), MEDA Pharma GmBH & Co. KG (Germany).

Article source: https://article-realm.com/article/Sports-Recreation/12805-Diabetic-Neuropathy-Treatment-Market-to-Reflect-Impressive-Growth-Rate-During-2018-2025.html